ArticleJournal of clinical laboratory analysis2025
Detection of bla
Article in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Temperature-Associated Prevalence and Multidrug Resistance ofAnimals : an open access journal from MDPI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEscherichia coli, a member of the Enterobacteriaceae family, is a leading cause of various infections. Carbapenems, a potent class of β-lactam antibiotics, serve as the last line of defense against multidrug-resistant bacteria. However, the global rise of carbapenemase-producing E. coli (CP-Ec), particularly metallo-β-lactamases (MBLs), poses a significant public health concern. This study aimed to determine the prevalence of bla
methodsA cross-sectional study was conducted on 80 meropenem-resistant E. coli strains isolated from clinical samples. Bacterial identification was performed using biochemical tests, including IMViC. Carbapenemase production was assessed using the modified carbapenem inactivation method (mCIM). Genotypic analysis of carbapenem-resistant strains was conducted via polymerase chain reaction (PCR) to detect bla
resultsThe mCIM phenotypic test identified 46.25% (37/80) of isolates as carbapenemase producers. PCR analysis revealed that bla
conclusionThe detection of bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.